Welcome to our dedicated page for TARGET GROUP news (Ticker: CBDY), a resource for investors and traders seeking the latest updates and insights on TARGET GROUP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TARGET GROUP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TARGET GROUP's position in the market.
Target Group Inc. (OTCQB: CBDY) announced that its subsidiary, Canary Rx Inc., has fulfilled approximately 665 kgs of craft cannabis worth over $1.9 million wholesale. These sales are attributed to partnerships across Canada facilitated through their Joint Venture, Venn Cannabis. CEO Tony Zarcone emphasized the importance of their partnerships with respected retail brands, highlighting the premium quality of their craft cannabis. The company aims to secure long-term contracts and predictable revenue streams to expand market reach and production capabilities.
Target Group Inc. (OTCQB: CBDY) announced that its subsidiary, Canary Rx Inc., has received a Health Canada sales license. This authorization allows Canary to manufacture and sell cannabis products to provincial distributors and authorized retailers, supporting its consumer packaged goods strategy. The company aims to deliver premium craft cannabis through its Ontario facility and expects to solidify its position in contract-based cultivation over the next 12-18 months. CEO Tony Zarcone emphasized the importance of this licensing milestone for executing their commercial strategy.
Target Group Inc. (CBDY) announced that its subsidiary, Canary Rx Inc., successfully completed its first three wholesale cannabis transactions through its joint venture, Venn Cannabis. This development signals a potential growth trajectory for the company in the Canadian cannabis market. Canary Rx aims to produce craft cannabis at its Simcoe, Ontario facility, enhancing its wholesale operations and establishing partnerships with licensed producers. The company expects these transactions to create significant revenue opportunities and strengthen its market position.
FAQ
What is the current stock price of TARGET GROUP (CBDY)?
What is the market cap of TARGET GROUP (CBDY)?
